These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 16402511)
1. ZD6474 headed for phase III trials in the fall. Oncology (Williston Park); 2005 Aug; 19(9):1140-2. PubMed ID: 16402511 [No Abstract] [Full Text] [Related]
2. Phase II data with ZD6474, a small-molecule kinase inhibitor of epidermal growth factor receptor and vascular endothelial growth factor receptor, in previously treated advanced non-small-cell lung cancer. Lee D Clin Lung Cancer; 2005 Sep; 7(2):89-91. PubMed ID: 16179094 [No Abstract] [Full Text] [Related]
3. Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions. Morabito A; Piccirillo MC; Falasconi F; De Feo G; Del Giudice A; Bryce J; Di Maio M; De Maio E; Normanno N; Perrone F Oncologist; 2009 Apr; 14(4):378-90. PubMed ID: 19349511 [TBL] [Abstract][Full Text] [Related]
4. Vandetanib for the treatment of non-small-cell lung cancer. Wong HL; de Boer RH Expert Opin Pharmacother; 2011 Oct; 12(14):2271-8. PubMed ID: 21819274 [TBL] [Abstract][Full Text] [Related]
5. ZD6474, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase, inhibits growth of experimental lung metastasis and production of malignant pleural effusions in a non-small cell lung cancer model. Matsumori Y; Yano S; Goto H; Nakataki E; Wedge SR; Ryan AJ; Sone S Oncol Res; 2006; 16(1):15-26. PubMed ID: 16783964 [TBL] [Abstract][Full Text] [Related]
6. Safety profile of combined therapy inhibiting EFGR and VEGF pathways in patients with advanced non-small-cell lung cancer: A meta-analysis of 15 phase II/III randomized trials. Ma W; Xu M; Liu Y; Liu H; Huang J; Zhu Y; Ji LJ; Qi X Int J Cancer; 2015 Jul; 137(2):409-19. PubMed ID: 25471638 [TBL] [Abstract][Full Text] [Related]
7. Two targets, one drug for new EGFR inhibitors. McNeil C J Natl Cancer Inst; 2006 Aug; 98(16):1102-3. PubMed ID: 16912259 [No Abstract] [Full Text] [Related]
9. Clairvoyance or reliable prediction of the future? van Zandwijk N; van de Vijver MJ Ann Oncol; 2007 Mar; 18(3):407-8. PubMed ID: 17322538 [No Abstract] [Full Text] [Related]
18. Molecular markers to predict response to gefitinib: EGFR, ErbB-2, or more? Normanno N; Di Maio M; Perrone F; Campiglio M J Clin Oncol; 2004 May; 22(10):2035-6; author reply 2036-7. PubMed ID: 15143103 [No Abstract] [Full Text] [Related]
19. Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR). Lee JS; Hirsh V; Park K; Qin S; Blajman CR; Perng RP; Chen YM; Emerson L; Langmuir P; Manegold C J Clin Oncol; 2012 Apr; 30(10):1114-21. PubMed ID: 22370318 [TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of angiogenesis inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis. Hong S; Tan M; Wang S; Luo S; Chen Y; Zhang L J Cancer Res Clin Oncol; 2015 May; 141(5):909-21. PubMed ID: 25373315 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]